Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study

Update Il y a 4 ans
Reference: NCT00526136

Woman and Man

Extract

To evaluate the safety, tolerability and efficacy of 3 doses of vernakalant (oral) (150 mg, 300 mg and 500 mg b.i.d.) administered for up to 90 days in subjects with sustained symptomatic atrial fibrillation (AF duration > 72 hours and < 6 months).


Inclusion criteria

  • Atrial fibrillation


Links